Latest & greatest articles for ace inhibitors

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on ace inhibitors or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on ace inhibitors and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ACE inhibitors

Angiotensin converting enzyme inhibitors (ACE) are principally used to reduce blood pressure. ACE inhibitors work by reducing the activity of the renin-angiotensin-aldosterone system. They have been used in a variety of conditions, including hypertension, acute myocardial infarctions, left ventricular systolic dysfunction and diabetic nephropathy

Ace inhibitors can be used alone to treat hypertension, or they can be used in combination with other drugs such as diuretics. Case studies and clinical trials on the medicine show that it can be used to prevent stroke or heart attacks. Common side effects of the drug including hypotension, dry cough, hyperkalaemia, headache, dizziness, fatigue, nausea, renal impairment and swelling in the lips and tongue.

ACE Inhibitors are widely used and feature extensively in the literature including clinical guidelines, systematic reviews, randomised controlled trials, case studies etc. These can easily be found via a search of the Trip Database. Medical research is vital to the development of new treatments and therapies for hypertension.

Top results for ace inhibitors

1. ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients

ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients View/ Open Date 2009-01 Format (...) Metadata Abstract Avoid prescribing an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB) for patients at high risk of vascular events or renal dysfunction. The combination does not reduce poor outcomes, and leads to more adverse drug-related events than an ACE inhibitor or ARB alone. Stength of recommendation: B: 1 large, high-quality randomized controlled trial (RCT). URI Part of Citation Journal of Family Practice, 58(1) 2009: 24+. Rights OpenAccess. This work

2019 PURLS

2. ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients

ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics ACE inhibitors and ARBs: One or the other -- not both -- for high-risk patients View/ Open Date 2009-01 Format (...) Metadata Abstract Avoid prescribing an angiotensin-converting enzyme (ACE) inhibitor and an angiotensin receptor blocker (ARB) for patients at high risk of vascular events or renal dysfunction. The combination does not reduce poor outcomes, and leads to more adverse drug-related events than an ACE inhibitor or ARB alone. Stength of recommendation: B: 1 large, high-quality randomized controlled trial (RCT). URI Part of Citation Journal of Family Practice, 58(1) 2009: 24+. Rights OpenAccess. This work

2019 PURLS

3. Angiotensin-converting enzyme (ACE) inhibitors versus angiotensin II receptor blockers (ARBs) for diabetic kidney disease: a Bayesian network meta-analysis of randomized controlled trials

Angiotensin-converting enzyme (ACE) inhibitors versus angiotensin II receptor blockers (ARBs) for diabetic kidney disease: a Bayesian network meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

4. ACE inhibitors and beta-blockers as risk factors for systemic reactions to venom immunotherapy: a systematic review and meta-analysis

ACE inhibitors and beta-blockers as risk factors for systemic reactions to venom immunotherapy: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record

2019 PROSPERO

5. ACE inhibitors

ACE inhibitors Top results for ace inhibitors - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 (...) or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for ace inhibitors The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other

2018 Trip Latest and Greatest

6. Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes and normal BP?

Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes and normal BP? Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes and normal BP? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes (...) and normal BP? View/ Open Date 2017-04 Format Metadata Abstract Q: Do ACE inhibitors or ARBs help prevent kidney disease in patients with diabetes and normal BP? Evidence-based answer: Yes for angiotensin-converting enzyme (ACE) inhibitors, no for angiotensin receptor blockers (ARBs). In normotensive patients with type 1 and type 2 diabetes, ACE inhibitor therapy reduces the risk of developing diabetic kidney disease, defined as new-onset microalbuminuria or macroalbuminuria, by 18% (strength

2018 Clinical Inquiries

7. ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes. (PubMed)

ACE Inhibitors and Statins in Adolescents with Type 1 Diabetes. Among adolescents with type 1 diabetes, rapid increases in albumin excretion during puberty precede the development of microalbuminuria and macroalbuminuria, long-term risk factors for renal and cardiovascular disease. We hypothesized that adolescents with high levels of albumin excretion might benefit from angiotensin-converting-enzyme (ACE) inhibitors and statins, drugs that have not been fully evaluated in adolescents.We (...) screened 4407 adolescents with type 1 diabetes between the ages of 10 and 16 years of age and identified 1287 with values in the upper third of the albumin-to-creatinine ratios; 443 were randomly assigned in a placebo-controlled trial of an ACE inhibitor and a statin with the use of a 2-by-2 factorial design minimizing differences in baseline characteristics such as age, sex, and duration of diabetes. The primary outcome for both interventions was the change in albumin excretion, assessed according

2017 NEJM Controlled trial quality: predicted high

8. Associations of centrally acting ACE inhibitors with cognitive decline and survival in Alzheimer’s disease (PubMed)

Associations of centrally acting ACE inhibitors with cognitive decline and survival in Alzheimer’s disease Cognitive improvement has been reported in patients receiving centrally acting angiotensin-converting enzyme inhibitors (C-ACEIs).To compare cognitive decline and survival after diagnosis of Alzheimer's disease between people receiving C-ACEIs, non-centrally acting angiotensin-converting enzyme inhibitors (NC-ACEIs), and neither.Routine Mini-Mental State Examination (MMSE) scores were (...) extracted in 5260 patients receiving acetylcholinesterase inhibitors and analysed against C-/NC-ACEI exposure at the time of Alzheimer's disease diagnosis.In the 9 months after Alzheimer's disease diagnosis, MMSE scores significantly increased by 0.72 and 0.19 points per year in patients on C-ACEIs and neither respectively, but deteriorated by 0.61 points per year in those on NC-ACEIs. There were no significant group differences in score trajectories from 9 to 36 months and no differences in survival.In

Full Text available with Trip Pro

2017 BJPsych open

9. Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice

Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice Prescrire IN ENGLISH - Spotlight ''Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice'', 1 June 2017 {1} {1} {1} | | > > > Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |    (...) |   |   |   |   |   |   |  Spotlight Hypertension and diabetes: if chlortalidone is unavailable, an ACE inhibitor should be the drug of choice Hypertension treatment in diabetes patients aims to reduce the risk of complications: cardiovascular events, end-stage renal failure, deterioration of eyesight. Patients with diabetes are exposed to arterial damage, including coronary artery disease and stroke, and damage to the blood capillaries

2017 Prescrire

11. ACE inhibitors during acute ST-elevation myocardial infarction (STEMI)

ACE inhibitors during acute ST-elevation myocardial infarction (STEMI)

2017 DynaMed Plus

12. Cohort study: ACE inhibitors in African Americans with hypertension associated with worse outcomes as compared to other antihypertensives

Cohort study: ACE inhibitors in African Americans with hypertension associated with worse outcomes as compared to other antihypertensives ACE inhibitors in African Americans with hypertension associated with worse outcomes as compared to other antihypertensives | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see (...) our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here ACE inhibitors in African Americans with hypertension associated with worse outcomes as compared to other antihypertensives

2016 Evidence-Based Medicine (Requires free registration)

13. Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor-Induced Angioedema: Guidelines

Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor-Induced Angioedema: Guidelines Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor-Induced Angioedema: Guidelines | CADTH.ca Find the information you need Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor-Induced Angioedema: Guidelines Treatment of Angiotensin Converting Enzyme (ACE) Inhibitor-Induced Angioedema: Guidelines Published on: November 26, 2015 Project Number: RB0938-000 Product Line: Research Type: Drug (...) Report Type: Summary of Abstracts Result type: Report Question What are the evidence-based guidelines regarding the treatment of patients with angiotensin-converting enzyme inhibitor-induced angioedema? Key Message Four evidence-based guidelines were identified regarding the treatment of patients with angiotensin-converting enzyme inhibitor-induced angioedema. Tags angioedema, angioneurotic edema, quincke's edema, angio-oedema, angiooedema Files Rapid Response Summary of Abstracts Published

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

14. Angiotensin-Converting Enzyme (ACE) Inhibitors: A Review of the Comparative Clinical and Cost-Effectiveness

Angiotensin-Converting Enzyme (ACE) Inhibitors: A Review of the Comparative Clinical and Cost-Effectiveness Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time (...) Enzyme (ACE) Inhibitors: A Review of the Comparative Clinical and Cost-Effectiveness DATE: 12 June 2015 CONTEXT AND POLICY ISSUES The use of angiotensin converting enzyme (ACE) inhibitors is a widespread practice and has several indications, mainly for hypertension (HTN), heart failure (HF), after an acute myocardial infarction (MI), and is also used for kidney protection in cases of chronic kidney disease and diabetic nephropathy. In 2007, there was a reported 18.0 million prescriptions of ACE

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

15. Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease. (PubMed)

Angiotensin-converting enzyme (ACE) inhibitors for proteinuria and microalbuminuria in people with sickle cell disease. Sickle cell disease is a group of disorders characterized by deformation of erythrocytes. Renal damage is a frequent complication in sickle cell disease as a result of long-standing anemia and disturbed circulation through the renal medullary capillaries. Due to the improvement in life expectancy of people with sickle cell disease, there has been a corresponding significant (...) increase in the incidence of renal complications. Microalbuminuria and proteinuria are noted to be a strong predictor of subsequent renal failure. There is extensive experience and evidence with angiotensin-converting enzyme (ACE) inhibitors over many years in a variety of clinical situations for patients who do not have sickle cell disease, but their effect in people with this disease is unknown. It is common practice to administer ACE inhibitors for sickle nephropathy due to their renoprotective

Full Text available with Trip Pro

2015 Cochrane

16. Icatibant in ACE-Inhibitor-Induced Angioedema. (PubMed)

Icatibant in ACE-Inhibitor-Induced Angioedema. 25946291 2015 05 11 2018 12 02 1533-4406 372 19 2015 05 07 The New England journal of medicine N. Engl. J. Med. Icatibant in ACE-inhibitor-induced angioedema. 1867-8 10.1056/NEJMc1503671 Baş Murat M Hoffmann Thomas K TK Kojda Georg G eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Angiotensin-Converting Enzyme Inhibitors 0 Bradykinin B2 Receptor Antagonists S8TIM42R2W Bradykinin AIM IM N Engl J Med. 2015 Jan 29;372(5):418-25 (...) 25629740 N Engl J Med. 2015 May 7;372(19):1866 25946292 N Engl J Med. 2015 May 7;372(19):1866 25946293 N Engl J Med. 2015 May 7;372(19):1867 25946294 Angioedema drug therapy Angiotensin-Converting Enzyme Inhibitors adverse effects Bradykinin analogs & derivatives Bradykinin B2 Receptor Antagonists therapeutic use Female Humans Male 2015 5 7 6 0 2015 5 7 6 0 2015 5 12 6 0 ppublish 25946291 10.1056/NEJMc1503671 10.1056/NEJMc1503671#SA4

2015 NEJM

17. Icatibant in ACE-Inhibitor-Induced Angioedema. (PubMed)

Icatibant in ACE-Inhibitor-Induced Angioedema. 25946292 2015 05 11 2018 12 02 1533-4406 372 19 2015 05 07 The New England journal of medicine N. Engl. J. Med. Icatibant in ACE-inhibitor-induced angioedema. 1866 10.1056/NEJMc1503671 Tomkiewicz William W eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Angiotensin-Converting Enzyme Inhibitors 0 Bradykinin B2 Receptor Antagonists S8TIM42R2W Bradykinin AIM IM N Engl J Med. 2015 Jan 29;372(5):418-25 25629740 N Engl J Med. 2015 May (...) 7;372(19):1867-8 25946291 Angioedema drug therapy Angiotensin-Converting Enzyme Inhibitors adverse effects Bradykinin analogs & derivatives Bradykinin B2 Receptor Antagonists therapeutic use Female Humans Male 2015 5 7 6 0 2015 5 7 6 0 2015 5 12 6 0 ppublish 25946292 10.1056/NEJMc1503671 10.1056/NEJMc1503671#SA1

Full Text available with Trip Pro

2015 NEJM

18. Icatibant in ACE-Inhibitor-Induced Angioedema. (PubMed)

Icatibant in ACE-Inhibitor-Induced Angioedema. 25946293 2015 05 11 2018 12 02 1533-4406 372 19 2015 05 07 The New England journal of medicine N. Engl. J. Med. Icatibant in ACE-inhibitor-induced angioedema. 1866 10.1056/NEJMc1503671 Soo Hoo Guy W GW Klaustermeyer William B WB eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Angiotensin-Converting Enzyme Inhibitors 0 Bradykinin B2 Receptor Antagonists S8TIM42R2W Bradykinin AIM IM N Engl J Med. 2015 Jan 29;372(5):418-25 25629740 N (...) Engl J Med. 2015 May 7;372(19):1867-8 25946291 Angioedema drug therapy Angiotensin-Converting Enzyme Inhibitors adverse effects Bradykinin analogs & derivatives Bradykinin B2 Receptor Antagonists therapeutic use Female Humans Male 2015 5 7 6 0 2015 5 7 6 0 2015 5 12 6 0 ppublish 25946293 10.1056/NEJMc1503671 10.1056/NEJMc1503671#SA2

Full Text available with Trip Pro

2015 NEJM

19. Icatibant in ACE-Inhibitor-Induced Angioedema. (PubMed)

Icatibant in ACE-Inhibitor-Induced Angioedema. 25946294 2015 05 11 2018 12 02 1533-4406 372 19 2015 05 07 The New England journal of medicine N. Engl. J. Med. Icatibant in ACE-inhibitor-induced angioedema. 1867 10.1056/NEJMc1503671 Armengol Guillaume G Faisant Charles C Benhamou Ygal Y eng Letter Comment United States N Engl J Med 0255562 0028-4793 0 Angiotensin-Converting Enzyme Inhibitors 0 Bradykinin B2 Receptor Antagonists S8TIM42R2W Bradykinin AIM IM N Engl J Med. 2015 Jan 29;372(5):418-25 (...) 25629740 N Engl J Med. 2015 May 7;372(19):1867-8 25946291 Angioedema drug therapy Angiotensin-Converting Enzyme Inhibitors adverse effects Bradykinin analogs & derivatives Bradykinin B2 Receptor Antagonists therapeutic use Female Humans Male 2015 5 7 6 0 2015 5 7 6 0 2015 5 12 6 0 ppublish 25946294 10.1056/NEJMc1503671 10.1056/NEJMc1503671#SA3

Full Text available with Trip Pro

2015 NEJM

20. A randomized trial of icatibant in ACE-inhibitor-induced angioedema. (PubMed)

A randomized trial of icatibant in ACE-inhibitor-induced angioedema. Angioedema induced by treatment with angiotensin-converting-enzyme (ACE) inhibitors accounts for one third of angioedema cases in the emergency room; it is usually manifested in the upper airway and the head and neck region. There is no approved treatment for this potentially life-threatening condition.In this multicenter, double-blind, double-dummy, randomized phase 2 study, we assigned patients who had ACE-inhibitor-induced (...) investigator-assessed symptom score) was significantly shorter with icatibant than with standard therapy (2.0 hours vs. 11.7 hours, P=0.03). The results were similar when patient-assessed symptom scores were used.Among patients with ACE-inhibitor-induced angioedema, the time to complete resolution of edema was significantly shorter with icatibant than with combination therapy with a glucocorticoid and an antihistamine. (Funded by Shire and the Federal Ministry of Education and Research of Germany

2015 NEJM Controlled trial quality: predicted high